Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen.
Vignani
F
F
Russo
L
L
Tucci
M
M
Motta
M
M
Vellani
G
G
Tampellini
M
M
Papotti
M
M
Dogliotti
L
L
Berruti
A
A
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002454:Cell Differentiation; D002945:Cisplatin / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D055099:Neuroendocrine Cells / Q000473:pathology*; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000473:pathology / Q000601:surgery*
D000970:Antineoplastic Agents; D002945:Cisplatin